Oramed Pharmaceuticals (ORMP) Stock: Buy, Sell, or Hold?
ORMP - Oramed Pharmaceuticals Inc.
$4.66
-0.10 (-2.10%)
âŧ
5d:
-5.48%
30d:
+9.13%
90d:
+22.63%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ORMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ORMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ORMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ORMP is currently trading at $4.66, which is considered fair relative to its 30-day fair value range of $4.42 to $5.05.
Technical Outlook: Technically, ORMP is in a uptrend. The price is currently testing key support at $4.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ORMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+50.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORMP is in a uptrend. The price is currently testing key support at $4.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ORMP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+50.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.42 -
$5.05
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.2% below Wall St target ($7.00)
- WARNING: Composite score 34/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.42 -
$5.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.65
Resistance Level
$5.15
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Wall Street Target
$7.00
(+50.2%)
Revenue Growth (YoY)
-100.0%
Earnings Growth (YoY)
493.5%
Share & Embed Analysis
Last updated: September 13, 2026 9:30 PM ET
Data refreshes hourly during market hours. Next update: 10:30 PM
Data refreshes hourly during market hours. Next update: 10:30 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
